title: Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
abstract: Acute myeloid leukemia (AML) is characterized by trilineage dysplasia, including atypical megakaryocytes. Acute megakaryoblastic leukemia (FAB M7) is particularly associated with atypical megakaryocytic hyperplasia (AMH). Fifteen patients with nonmegakaryoblastic AML developed AMH after therapy, comprising 12.6% of cases of AML diagnosed from 1986 to 1989. Platelet counts were normal in nine patients and decreased in six. Blasts comprised less than 5% of cells in 40% of the biopsies, ranged from 5-15% in 53%, and comprised more than 30% of cells in 7%. Numerous small hypo- and hyperlobated megakaryocytes were seen in all specimens, often occurring in clusters, and were more easily seen in sections than in smears. Subsequent biopsies in 13 patients showed a remission marrow in seven, increased blasts in three, and AML in three; none showed AMH. AMH resembling acute megakaryoblastic leukemia may be seen transiently after treatment of AML.
authors.affiliation: Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106.
authors.forename: N S
authors.initials: NS
authors.lastname: Rosenthal
authors.forename: D C
authors.initials: DC
authors.lastname: Farhi
mesh_terms: D000208:Acute Disease; D015703:Antigens, CD / Q000276:immunology; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia / Q000473:pathology; D016130:Immunophenotyping; D007947:Leukemia, Megakaryoblastic, Acute / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008533:Megakaryocytes / Q000473:pathology; D008942:Mitoxantrone / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D011379:Prognosis; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D003561:Cytarabine; D005047:Etoposide; D004317:Doxorubicin; D008942:Mitoxantrone; D003630:Daunorubicin